Thank you for participating in the Botox Survey for CADTH. We value your experience, opinions and ideas. You should be finished the survey in less than 15 minutes.
This survey is intended only for patients currently receiving onabotulinum toxin type A (referred to in this document as Botox for simplicity) and will be diffused in clinics performing Botox injections.
Reimbursement for Botox treatments for migraine by public drug coverage plans will be determined by an evaluation by a Canadian institution called CADTH. In Quebec, a similar process takes place and is led by an institution called INESSS.
Migraine Canada/Migraine Quebec wish to partner to gather the voices of migraine patients and submit a Patient Review to CADTH/INESSS.
This survey does not collect any personally identifiable information, and your answers will remain anonymous.
Thank you for taking the time to complete this survey!